GRIA2 and Alzheimer disease: Our study identified a clear reduction in AMPAR protein levels in the hippocampus of AD patients (see Supplementary Figure 2), consistent with the reported down-regulation in the expression of GluA1 and GluA2 in AD (Martín-Belmonte et al., 2019).